The Allergic Rhinitis (AR) Allergen Specific Immunotherapy (ASIT) market is expected to grow from $901m in 2018 to $1.14bn in 2028 across the seven major markets (7MM*) at a modest compound annual growth rate (CAGR) of 2.3%, according to GlobalData, a leading data and analytics company.
The company’s latest report: ‘Allergic Rhinitis Immunotherapy: Opportunity Analysis and Forecasts to 2028’, reveals that between 2018 and 2028, growth in the AR ASIT market will be driven primarily by the anticipated approval and launch of five pipeline therapies. These include three short-course, pre-seasonal grass pollen subcutaneous immunotherapy (SCIT) products, Allergy Therapeutics’ Pollinex Quattro Grass, ASIT Biotech’s gp-ASIT, and Biomay’s BM-32, as well as two sublingual immunotherapy (SLIT) tablet products, ALK-Abello’s Itulazax and Shionogi’s/Stallergenes Greer’s S-525606/STG-120, targeting birch pollen and Japanese cedar pollen (JCP) allergies respectively.
Rose Joachim, PhD, Senior Pharma Analyst at GlobalData explains: “Sales growth will be particularly pronounced in the US and Japan, where the use of more costly pre-formulated ASIT products is expected to increase. In the US this includes the anticipated launch of Pollinex Quattro Grass, which is expected to reach sales of $138m by 2028. In Japan, the size of the ASIT market has been steadily growing since the launch of several pre-formulated SLIT products in 2014, the recent launch of Torii’s Japanese cedar pollen (JCP) SLIT tablet, Cedarcure, and the expected launch of Shionogi’s S-525606 are expected to further drive market growth.”
Although the majority of pipeline ASIT products are expected to launch in the five European markets (5EU**), growth is expected to be fairly stagnant in this region, with a CAGR of only 0.5% during the forecast period. Attenuated growth is likely a product of the ongoing flux in the regulation and coverage of ASIT products by national healthcare services.
Joachim explains: “In the 5EU there is an increasing focus on the use of ASIT products with greater clinical accountability, particularly those with formal marketing authorization. Although this shift away from a market dominated by named patient products makes room for new players such as ASIT Biotech’s gp-ASIT, Biomay’s BM-32, and ALK-Abello’s Itulazax, these new products will likely replace other products without necessarily drawing in huge numbers of new patients. Thus, despite great changes to the marketplace, it is unlikely that sales growth will be very significant during the forecast period.”
Despite being the only disease-modifying therapy available for the treatment of AR, ASIT remains underused. Key opinion leaders (KOLs) interviewed by GlobalData suggest that this is in great part due to a number of lingering unmet needs in the field. These include needs for improved insurance coverage for ASIT products, increased access to allergy-specialists, changes in the way ASIT products are regulated, and strategies to improve ASIT compliance and persistence.
Joachim concludes: “Although these unmet needs stand as barriers to the increased usage of ASIT in the 7MM, they provide industry members a great amount of opportunity to transform the market going forward.”
*7MM = US, France, Germany, Italy, Spain, UK, and Japan
**5EU = France, Germany, Italy, Spain, and UK